Pemigatinib (Pemazyre)
Current understanding
To be populated as evidence accumulates.
Evidence log
- April 28, — FDA Approves Pemazyre (Pemigatinib) for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: FDA approved pemigatinib as first targeted therapy for relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement based on FIGHT-203 phase 2 trial showing 78% complete response rate in chronic phase disease (trial-early). (novelty: 4)
Open questions
Related
Contributing findings
FDA Approves Pemazyre (Pemigatinib) for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
April 28, 2026
novelty 4
per-area 4
introduces